WO2011071314A2 - Processes for preparing crystalline forms a and b of ilaprazole and process for converting the crystalline forms - Google Patents

Processes for preparing crystalline forms a and b of ilaprazole and process for converting the crystalline forms Download PDF

Info

Publication number
WO2011071314A2
WO2011071314A2 PCT/KR2010/008767 KR2010008767W WO2011071314A2 WO 2011071314 A2 WO2011071314 A2 WO 2011071314A2 KR 2010008767 W KR2010008767 W KR 2010008767W WO 2011071314 A2 WO2011071314 A2 WO 2011071314A2
Authority
WO
WIPO (PCT)
Prior art keywords
ilaprazole
acid
crystalline form
reaction solvent
preparing
Prior art date
Application number
PCT/KR2010/008767
Other languages
French (fr)
Other versions
WO2011071314A3 (en
Inventor
Dong Yeon Kim
Jae Soo Shin
Jun Yeoun Lee
Kwi Hyung Cho
Sung Tae Park
Jung Woo Kim
Sang Don Nam
Hee Yun Kim
Original Assignee
Il-Yang Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il-Yang Pharm. Co., Ltd. filed Critical Il-Yang Pharm. Co., Ltd.
Priority to BR112012012212A priority Critical patent/BR112012012212A2/en
Priority to EA201200716A priority patent/EA019058B1/en
Priority to IN3176DEN2012 priority patent/IN2012DN03176A/en
Priority to UAA201207006A priority patent/UA102787C2/en
Publication of WO2011071314A2 publication Critical patent/WO2011071314A2/en
Publication of WO2011071314A3 publication Critical patent/WO2011071314A3/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Definitions

  • the present invention relates to novel processes for preparing crystalline forms A and B of ilaprazole and the conversion of these crystalline forms.
  • Gastric and duodenal ulcers are a gastrointestinal disease caused by various factors such as mental stress, dietary habits, intake of irritable food, and the like.
  • the direct cause of peptic ulcers is damage to the gastric membrane due to excessive secretion of gastric acid.
  • therapeutic agents which have been commonly used for treatment of the peptic ulcers include, for example, antacids for neutralizing gastric acid, anti-pepsin agents, agents for protecting the gastric mucous membrane, anti-cholinergic agents for inhibiting gastric secretion, para-sympatholytic agents, H 2 -receptor antagonists, and the like.
  • H 2 -receptor antagonists as agents for treating gastric and duodenal ulcers has increased.
  • PPI formulations such as omeprazole have demonstrated excellent anticancer effects compared to existing H 2 receptor antagonists, including cimetidine, famotidine and ranitidine, and thus various PPI formulations have been developed and widely used.
  • the present inventors conducted studies for a long timeto develop a novel PPI compound and, as a result, invented ilaprazole, a compound having reduced side effects and high therapeutic effects compared to existing PPI compounds.
  • the invented ilaprazole was patented in many countries, including Korea (Korean Patent Application No. 10-1994-3833).
  • the following reaction scheme 1 shows a general process for preparing ilaprazole.
  • the physical or chemical properties of a drug can vary depending on the crystalline form of the drug, and such physical and chemical properties can greatly influence a suitable dosage form of the drug, the optimization of a process for preparing the drug, and the in vivo absorption of the drug.
  • the discovery of the most appropriate crystalline form of a drug in a procedure for developing the drug enables the development time and cost to be reduced.
  • International Patent Publication No. WO 2008/083333 discloses polymorphic forms of racemic ilaprazole and processes for preparing the same. According to the disclosure of WO 2008/083333, the crystalline form A of racemic ilaprazole is the most thermodynamically stable of these crystalline forms.
  • the crystalline form A is not easily dissolved in organic solvents containing water, but it is the most bio-available form, and thus is the most appropriate dosage form.
  • the crystalline form B of racemic ilaprazole can crystallize in pure form from aprotic solvents such as acetone/TEA, and thus has an advantage in that it can be purified during the preparation process.
  • the XRPD diffraction patterns of the crystalline forms A and B of racemic ilaprazole disclosed in International Patent Publication No. WO 2008/083333 are shown in Tables 1 and 2 below.
  • the DSC onset temperature of the crystalline form A of ilaprazole is 167 °C (max 170 °C)
  • the DSC onset temperature of the crystalline form of ilaprazole is 159 °C (max 163 °C).
  • the following reaction schemes 2 and 3 show processes for preparing crystalline forms A and B of ilaprazole, disclosed in International Patent Publication No. 2008/083333.
  • the process for preparing the crystalline form A of ilaprazole according to reaction scheme 2 above has the following shortcomings: 1) large amounts of various solvents are used in crystallization; 2) the preparation process is complex, because a concentration process should be carried out several times; 3) it is difficult to obtain the pharmaceutically required purity; and 4) a complex crystallization process is used, thus making it difficult to obtain the pure crystalline form A of ilaprazole.
  • the yield of the crystalline form A can be reduced when a process for increasing the purity is carried out, and also in that, because the amount of solvent used is large, the preparation process is not economical and can adversely affect the health of workers.
  • the process for preparing the crystalline form B of ilaprazole according to reaction scheme 3 above has the following shortcomings: 1) because the preparation process is a process of treating the already prepared crystalline form A, a process of preparing the crystalline form B is required; 2) the preparation process is time-consuming, because the crystallization process for obtaining the crystalline form B is continuously carried out for 11 days; and 3) the preparation process is not economical, because the use of an additional solvent is required in order to further treat the already prepared crystalline form A and because the additional process for treating the crystalline form A is carried out to reduce the yield of the crystalline form B. In addition, the preparation process is not suitable for mass production, and thus in some cases, the uniform crystalline form B is not obtained and the partially crystalline or non-uniform crystalline form B is obtained.
  • the present invention has been made in order to more efficiently solve the above-described problems occurringin the prior art.
  • the present invention adopts an industrially simple process compared to existing processes, enables a large amount of the pure crystalline form A of ilaprazole to be reproducibly obtained, is suitable for mass production, and allows the uniform crystalline form B of ilaprazole to be reproducibly obtained.
  • the present invention provides processes for preparing crystalline forms A and B of ilaprazole of the following formula 1 and a process for converting the crystalline forms, which enable the compounds to be obtained with high purity at low production cost in a shortened reaction time and show a reduced number of reaction processes and a high yield:
  • the present invention provides processes for preparing crystalline forms A and B of ilaprazole of the following formula 1 and a process for converting the crystalline forms:
  • the process for preparing crystalline A of ilaprazole according to the present invention includes the steps of: 1) preparing an inorganic salt of ilaprazole or a hydrate thereof from ilaprazole in the presence of an inorganic base and a reaction solvent; and 2) neutralizing the produced inorganic salt of ilaprazole or the hydrate thereof with an acid in a reaction solvent to prepare the crystalline form A of ilaprazole.
  • the process for preparing the crystalline form A of ilaprazole A according to the present invention may additionally include, after step 1), a step of adding a heterogeneous inorganic salt to prepare a heterogeneous inorganic salt of ilaprazole or a hydrate thereof.
  • the inorganic base or inorganic salt that is used in the step of preparing the inorganic salt or inorganic salt hydrate of ilaprazole may include lithium, titanium, barium, zinc, sodium, potassium, calcium, magnesium and/or strontium.
  • it may include zinc, sodium, potassium, calcium, magnesium and/or strontium. More preferably, it may include sodium, potassium, calcium, magnesium and/or strontium.
  • reaction solvent that is used in the step of preparing the inorganic salt or inorganic salt hydrate of ilaprazole may be a lower (C 1 ⁇ C 6 ) alkanol and/or a polar solvent.
  • the reaction solvent that is used in step 1 may be at least one selected from the group consisting of methanol, ethanol, propanol, xylene, toluene, tetrahydrofuran, 1,2-dichloroethane, acetone, ether, dichloromethane, acetonitrile, dimethylsulfoxide, dimethylformamide, and mixtures thereof.
  • it may be at least one selected from the group consisting of methanol, ethanol, propanol, tetrahydrofuran, acetone, and mixtures thereof. More preferably, it may be methanol, ethanol and/or propanol.
  • step 1) of preparing the inorganic salt or inorganic salt hydrate of ilaprazole may be performed by stirring the mixture at a temperature of 0 to 150 °C preferably 0 to 80 °C and more preferably room temperature to 50 °C but the stirring temperature is not specifically limited. Also, the stirring may preferablybe carried out, but the stirring time is not specifically limited.
  • the acid that is used in step 2) of preparing the crystalline form A of ilaprazole by neutralization with the acid may be at least one selected from the group consisting of chloroacetic acid, benzoic acid, butyric acid, sulfuric acid, hydrochloric acid, phosphoric acid, nitric acid, perchloric acid, formic acid, acetic acid, propionic acid, succinic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, hydroxybenzenesulfonic acid and tartaric acid.
  • it may be at least one selected from the group consisting of chloroacetic acid, benzoic acid, butyric acid, sulfuric acid, hydrochloric acid, phosphoric acid, nitric acid, perchloric acid, formic acid and acetic acid. More preferably, it may be benzoic acid, formic acid and/or acetic acid.
  • the reaction solvent that is used in step 2) of preparing the crystalline form A of ilaprazole may be a lower (C 1 ⁇ C 6 ) alkanol and/or a polar solvent.
  • the reaction solvent that is used in step 2) may be at least one selected from the group consisting of methanol, ethanol, propanol, xylene, toluene, tetrahydrofuran, 1,2-dichloromethane, acetone, ether, dichloromethane, acetonitrile, dimethylsulfoxide, dimethylformamide, and mixtures thereof.
  • it may be at least one selected from the group consisting of methanol, ethanol, propanol, tetrahydrofuran, acetone, and mixtures thereof. More preferably, it may be methanol, ethanol and/or propanol.
  • step 2) of preparing the crystalline form A of ilaprazole may be performed by stirringthe mixture at a temperature of 0 to 150 °C, preferably 0 to 80 °C, and more preferably room temperature to 50 °C, but the stirring temperature is not specifically limited. Also, the stirring may preferably be carried out for 1-6 hours, but the stirring time is not specifically limited.
  • the process for preparing the crystalline form B of ilaprazole according to the present invention may include a step of preparing the crystalline form B of ilaprazole from ilaprazole in a reaction solvent.
  • the reaction solvent that is used in the step of preparing the crystalline form B of ilaprazole may be a lower (C 1 ⁇ C 6 ) alkanol and/or a polar solvent.
  • the reaction solvent that is used in this step may be at least one selected from the group consisting of tetrahydrofuran, 1,2-dichloroethane, methanol, ethanol, propanol, acetone, dichloromethane, diethylether, ethylacetate, and mixtures thereof. More preferably, it may be at least one selected from the group consisting of methanol, ethanol, acetone, dichloromethane, diethylether, ethylacetate, and mixtures thereof.
  • a stabilizing agent may be added to the reaction solvent.
  • a stabilizing agent that may be used in this step is not specifically limited, but it may be at least one selected from the group consistingof, for example, triethylamine, diethylamine, ethylenediamine, trimethylamine, diisopropylethylamine and pyridine.
  • the step of preparing the crystalline form B of ilaprazole may be performed by stirring the mixture at a temperature of 30 to 150 °C, preferably 0 to 150 °C, more preferably 0 to 80 °C, and even more preferably room temperature to 50 °C,but the stirring temperature is not specifically limited. Also, the stirring may preferably be carried out for 1-6 hours, but the stirring time is notspecifically limited.
  • the starting material ilaprazole may be non-crystallized ilaprazole such as crude ilaprazole.
  • the process for converting crystalline forms of ilaprazole according to the present invention may include a step of converting the crystalline form A into crystalline form B of ilaprazole or converting the crystalline form B into crystalline form A of ilaprazole.
  • a solvent that may be used when preparing the crystalline form B from ilaprazole may be used.
  • an inorganic salt, a reaction solvent and/or an acid which may be used when preparing the crystalline form A from ilaprazole, may be used.
  • FIG. 1 is the XRPD diffraction pattern of the crystalline form A of ilaprazole according to the present invention
  • FIG. 2 is the DSC thermogram of the crystalline form A of ilaprazole according to the present invention
  • FIG. 3 is the IR spectrum of the crystalline form A of ilaprazole according to the present invention.
  • FIG. 4 is the 1 H-NMR spectrum of the crystalline form A of ilaprazole according to the present invention.
  • FIG. 5 is the XRPD diffraction pattern of the crystalline form B of ilaprazole according to the present invention.
  • FIG. 6 is the DSC thermogram of the crystalline form B of ilaprazole according to the present invention.
  • FIG. 7 is the IR spectrum of the crystalline form B of ilaprazole according to the present invention.
  • FIG. 8 is the 1 H-NMR spectrum of the crystalline form B of ilaprazole according to the present invention.
  • Ilaprazole sodium salt (12.87 mole, 5.0 kg) was added to 100 L of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 20 L of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °Cfor 12 hours, thereby obtaining 4.06 kg (86% yield) of the pure title compound as white crystalline powder.
  • the results of analysis of the obtained powder are as follows.
  • Ilaprazole sodium salt (25.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of benzoic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °Cfor 12 hours, thereby obtaining 7.7 g (82% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole sodium salt (25.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of formic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °Cfor 12 hours, thereby obtaining 8.1 g (86% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole potassium salt (24.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °C for 12 hours, thereby obtaining 7.4 g (82% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole calcium salt trihydrate (12.1 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours.Then, the produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °C for 12 hours, thereby obtaining 7.5 g (84% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole potassium salt (24.7 mmole, 10.0 g) was dissolved in 20 ml of water, and magnesium chloride (49.4 mmole, 4.7 g)was added thereto. Then, the mixture was stirred at room temperature for 4 hours. The produced solid was filtered, washed with 25 ml of methanol, and then dried at 40 °C for 12 hours, thereby obtaining 8.7 g (89% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole potassium salt (24.7 mmole, 10.0 g) was dissolved in 20 ml of water, and magnesium chloride (49.4 mmole, 4.7 g)was added thereto. Then, the mixture was stirred at room temperature for 4 hours. The produced solid was filtered, added to 75 ml of water and stirred at room temperature for 6 hours. The resulting solid was filtered, washed with 25 ml of methanol, and then dried at 40 °C for 12 hours, thereby obtaining 7.5 g (75% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole sodium salt (25.7 mmole, 10.0 g) was dissolved in 130 ml of water, and a solution of magnesium chloride (12.9 mmole, 1.2 g)in 48 ml of water was added thereto. Then, the mixture was stirred at room temperature for 1 hour. The produced solid was filtered, washed with 30 ml of water, and then dried at 40 °Cfor 12 hours, thereby obtaining 9.8 g (92% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole magnesium salt tetrahydrate (12.1 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acd. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °C for 12 hours, thereby obtaining 7.4 g (83% yield) of the pure title compound as white crystalline powder.
  • Strontium chloride (hexahydrate) (30.9 mmole, 8.2 g) was dissolved in 120 mlof methanol, and a solution of ilaprazole sodium salt (51.5 mmole, 20.0 g) in 120 ml of water was added thereto. Then, the produced solid was filtered, washed with 120 ml of a mixed solvent of water and methanol, and then dried at 40 °C for 12hours, thereby obtaining 17.2 g (78% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole strontium salt dehydrate (11.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 °Cfor 12 hours, thereby obtaining 7.0 g (82% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole (16.38 mole, 6.0 kg) was dissolved in 30 L of a mixed solvent of methanol and dichloromethane and added slowly to 150 L of diethylether. Then, the mixture was stirred at room temperature for 45 minutes. The producedsolid was filtered, washed with 3 L of diethylether, and then dried at 30 °C for 12 hours, thereby obtaining 5.1 kg (85% yield) of the pure title compound as white crystalline powder.
  • the results of analysis of the obtained powder are as follows.
  • Ilaprazole (54.6 mmole, 20.0 g) was dissolved in 260 ml of dichloromethane, and the solutionwas concentrated under reduced pressure to a volume of 80 ml.
  • the concentrated ethyl acetate solution was added slowly to 266 ml of ethyl acetate, and then stirred at a temperature between -10 °C and -15 °C for about 3-4 hours.
  • the produced solid was filtered, washed with 100 ml of diethylether, and then dried at 30 °C for 12 hours, thereby obtaining 17.8 g (89% yield) of the pure title compound as white crystalline powder.
  • Ilaprazol (27.3 mmole, 10.0 g) was dissolved in 130 ml of a mixed solvent of dichloromethane and triethylamine (1%, v/v), and 150 ml of acetone was added thereto. Then, the solution was concentrated under reduced pressure to a volume of 130 ml.130 ml of diethylether was added slowly to the concentrated solution, and the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 100 ml of diethylether, and then dried at 30 °C for 12 hours, thereby obtaining 8.1 g (81% yield) of the pure title compound as white crystalline powder.
  • Ilaprazole (27.3 mmole, 10.0 g) was dissolved in 130 ml of a mixed solvent of dichloromethane and triethylamine (1%, v/v), and 130 ml of diethylether was slowly added thereto. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 100 ml of diethylether, and then dried at 30 °C for 12 hours, thereby obtaining 7.6 g (76%yield) of the pure title compound as white crystalline powder.
  • Example 23 Conversion of crystalline form B of ilaprazole into crystalline form A of illaprazole
  • ilaprazole sodium salt (49.2 mmole, 19.1 g) was added to 380 mlof ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid.
  • Example 24 Conversion of crystalline form A of ilaprazole into crystalline form B of ilaprazole
  • the crystalline form A of ilaprazole (54.6 mmole, 20.0 g) was dissolved in 100 ml of a mixed solvent of methanol and dichloromethane and added slowly to 500 ml of diethylether. Then, the mixture was stirred at room temperature for 45 minutes. The produced solid was filtered, washed with 200 ml of diethylether, and then dried at 30 °C for 12 hours, thereby obtaining 16.6 g (83% yield) of the pure title compound as white crystalline powder.
  • 0.5% ammonia water/ethanol (1.0 kg) was placed in the flask, and dichloromethane (2.4 kg) was added thereto. Then, the solution was concentrated under reduced pressure at a temperature of 20 to 25 °C to a volume of about 1.0 L. 0.5% ammonia water/ethanol (1.2 kg) was placed in the flask, and the solution was concentrated again under reduced pressure at a temperature of 20 to 25 °C to a volume of about 1.2 L. 0.5% ammonia water/ethanol (0.2 kg) was added to the concentrated solution, and the solution was cooled to about 5 °C and then stirred for 45 minutes.
  • the resulting slurry was filtered and washed with 0.5% ammonia water/ethanol (0.2 kg), ethanol (0.2 kg) and MTBE (2 x 0.2 kg).
  • the filtered solid was dried for 2 hours and vacuum-dried at a temperature of 92 °C or below for 92 hours, thereby obtaining 0.338 kg (85% yield) of the crystalline form A of ilaprazole.
  • the crystalline form A of ilaprazole was added to 10 ml of acetone/triethylamine and sonicated at room temperature for about 5 minutes to make a saturated solution of ilaprazole.
  • the slurry was filtered through a nylon filter into a glass vial.
  • the filtered slurry was allowed to stand in a refrigerator for 11 days and then filtered, thereby obtaining a white crystalline form B of ilaprazole.

Abstract

Disclosed are novel processes for preparing crystalline forms A and B of ilaprazole of formula 1 and the conversion of these crystalline forms. The novel processes include a process of preparing the crystalline form A of high purity by preparing an inorganic salt of ilaprazole or a hydrate thereof and then neutralizing the prepared inorganic salt of ilaprazole or the hydrate thereof with an acid in an organic solvent (single solvent or mixed solvent) a process of preparing the crystalline form B of high purity by removing impurities from ilaprazole using an organic solvent (single solvent or mixed solvent); and a process of conversion from the crystalline A into the crystalline form B or from the crystalline form B into the crystalline form A.

Description

PROCESSES FOR PREPARING CRYSTALLINE FORMS A AND B OF ILAPRAZOLE AND PROCESS FOR CONVERTING THE CRYSTALLINE FORMS
The present invention relates to novel processes for preparing crystalline forms A and B of ilaprazole and the conversion of these crystalline forms.
Gastric and duodenal ulcers are a gastrointestinal disease caused by various factors such as mental stress, dietary habits, intake of irritable food, and the like. The direct cause of peptic ulcers is damage to the gastric membrane due to excessive secretion of gastric acid. Accordingly, therapeutic agents which have been commonly used for treatment of the peptic ulcers include, for example, antacids for neutralizing gastric acid, anti-pepsin agents, agents for protecting the gastric mucous membrane, anti-cholinergic agents for inhibiting gastric secretion, para-sympatholytic agents, H2-receptor antagonists, and the like. At the present time, since it has been disclosed that antacids and CNS-acting antiulcerants provide only an unsatisfactory therapeutic effect and may cause adverse effects when they are administered for a long period, the use of H2-receptor antagonists as agents for treating gastric and duodenal ulcers has increased.
Moreover, PPI formulations such as omeprazole have demonstrated excellent anticancer effects compared to existing H2 receptor antagonists, including cimetidine, famotidine and ranitidine, and thus various PPI formulations have been developed and widely used. Meanwhile, the present inventors conducted studies for a long timeto develop a novel PPI compound and, as a result, invented ilaprazole, a compound having reduced side effects and high therapeutic effects compared to existing PPI compounds. The invented ilaprazole was patented in many countries, including Korea (Korean Patent Application No. 10-1994-3833). The following reaction scheme 1 shows a general process for preparing ilaprazole.
[Reaction Scheme 1]
[Corrected under Rule 26 24.02.2011]
Figure WO-DOC-CHEMICAL-5
The physical or chemical properties of a drug can vary depending on the crystalline form of the drug, and such physical and chemical properties can greatly influence a suitable dosage form of the drug, the optimization of a process for preparing the drug, and the in vivo absorption of the drug. The discovery of the most appropriate crystalline form of a drug in a procedure for developing the drug enables the development time and cost to be reduced. International Patent Publication No. WO 2008/083333 discloses polymorphic forms of racemic ilaprazole and processes for preparing the same. According to the disclosure of WO 2008/083333, the crystalline form A of racemic ilaprazole is the most thermodynamically stable of these crystalline forms. The crystalline form A is not easily dissolved in organic solvents containing water, but it is the most bio-available form, and thus is the most appropriate dosage form. The crystalline form B of racemic ilaprazole can crystallize in pure form from aprotic solvents such as acetone/TEA, and thus has an advantage in that it can be purified during the preparation process. The XRPD diffraction patterns of the crystalline forms A and B of racemic ilaprazole disclosed in International Patent Publication No. WO 2008/083333 are shown in Tables 1 and 2 below.
[Table 1]
XPRD diffraction pattern of crystalline form A of ilaprazole
Figure PCTKR2010008767-appb-I000002
[Table 2]
XPRD diffraction pattern of crystalline form B of ilaprazole
Figure PCTKR2010008767-appb-I000003
Also, according to the disclosure of International Patent Publication No. 2008/083333, the DSC onset temperature of the crystalline form A of ilaprazole is 167 ℃ (max 170 ℃), and the DSC onset temperature of the crystalline form of ilaprazole is 159 ℃ (max 163 ℃). The following reaction schemes 2 and 3 show processes for preparing crystalline forms A and B of ilaprazole, disclosed in International Patent Publication No. 2008/083333.
[Reaction Scheme 2]
[Corrected under Rule 26 24.02.2011]
Figure WO-DOC-CHEMICAL-16
[Reaction Scheme 3]
[Corrected under Rule 26 24.02.2011]
Figure WO-DOC-CHEMICAL-18
The process for preparing the crystalline form A of ilaprazole according to reaction scheme 2 above has the following shortcomings: 1) large amounts of various solvents are used in crystallization; 2) the preparation process is complex, because a concentration process should be carried out several times; 3) it is difficult to obtain the pharmaceutically required purity; and 4) a complex crystallization process is used, thus making it difficult to obtain the pure crystalline form A of ilaprazole. In addition, there are disadvantages in that the yield of the crystalline form A can be reduced when a process for increasing the purity is carried out, and also in that, because the amount of solvent used is large, the preparation process is not economical and can adversely affect the health of workers.
The process for preparing the crystalline form B of ilaprazole according to reaction scheme 3 above has the following shortcomings: 1) because the preparation process is a process of treating the already prepared crystalline form A, a process of preparing the crystalline form B is required; 2) the preparation process is time-consuming, because the crystallization process for obtaining the crystalline form B is continuously carried out for 11 days; and 3) the preparation process is not economical, because the use of an additional solvent is required in order to further treat the already prepared crystalline form A and because the additional process for treating the crystalline form A is carried out to reduce the yield of the crystalline form B. In addition, the preparation process is not suitable for mass production, and thus in some cases, the uniform crystalline form B is not obtained and the partially crystalline or non-uniform crystalline form B is obtained.
Accordingly, the present invention has been made in order to more efficiently solve the above-described problems occurringin the prior art. The present invention adopts an industrially simple process compared to existing processes, enables a large amount of the pure crystalline form A of ilaprazole to be reproducibly obtained, is suitable for mass production, and allows the uniform crystalline form B of ilaprazole to be reproducibly obtained.
The present invention provides processes for preparing crystalline forms A and B of ilaprazole of the following formula 1 and a process for converting the crystalline forms, which enable the compounds to be obtained with high purity at low production cost in a shortened reaction time and show a reduced number of reaction processes and a high yield:
[Formula 1]
Figure PCTKR2010008767-appb-I000006
(Ilaprazole)
The present invention provides processes for preparing crystalline forms A and B of ilaprazole of the following formula 1 and a process for converting the crystalline forms:
[Formula 1]
Figure PCTKR2010008767-appb-I000007
(Ilaprazole)
The process for preparing crystalline A of ilaprazole according to the present invention includes the steps of: 1) preparing an inorganic salt of ilaprazole or a hydrate thereof from ilaprazole in the presence of an inorganic base and a reaction solvent; and 2) neutralizing the produced inorganic salt of ilaprazole or the hydrate thereof with an acid in a reaction solvent to prepare the crystalline form A of ilaprazole.
The process for preparing the crystalline form A of ilaprazole A according to the present invention may additionally include, after step 1), a step of adding a heterogeneous inorganic salt to prepare a heterogeneous inorganic salt of ilaprazole or a hydrate thereof.
In the present invention, the inorganic base or inorganic salt that is used in the step of preparing the inorganic salt or inorganic salt hydrate of ilaprazole may include lithium, titanium, barium, zinc, sodium, potassium, calcium, magnesium and/or strontium. Preferably, it may include zinc, sodium, potassium, calcium, magnesium and/or strontium. More preferably, it may include sodium, potassium, calcium, magnesium and/or strontium.
In the present invention, thereaction solvent that is used in the step of preparing the inorganic salt or inorganic salt hydrate of ilaprazole may be a lower (C1~C6) alkanol and/or a polar solvent. Specifically, the reaction solvent that is used in step 1 may be at least one selected from the group consisting of methanol, ethanol, propanol, xylene, toluene, tetrahydrofuran, 1,2-dichloroethane, acetone, ether, dichloromethane, acetonitrile, dimethylsulfoxide, dimethylformamide, and mixtures thereof. Preferably, it may be at least one selected from the group consisting of methanol, ethanol, propanol, tetrahydrofuran, acetone, and mixtures thereof. More preferably, it may be methanol, ethanol and/or propanol.
In the present invention, step 1) of preparing the inorganic salt or inorganic salt hydrate of ilaprazole may be performed by stirring the mixture at a temperature of 0 to 150 ℃ preferably 0 to 80 ℃ and more preferably room temperature to 50 ℃ but the stirring temperature is not specifically limited. Also, the stirring may preferablybe carried out, but the stirring time is not specifically limited.
In the present invention, the acid that is used in step 2) of preparing the crystalline form A of ilaprazole by neutralization with the acid may be at least one selected from the group consisting of chloroacetic acid, benzoic acid, butyric acid, sulfuric acid, hydrochloric acid, phosphoric acid, nitric acid, perchloric acid, formic acid, acetic acid, propionic acid, succinic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, hydroxybenzenesulfonic acid and tartaric acid. Preferably, it may be at least one selected from the group consisting of chloroacetic acid, benzoic acid, butyric acid, sulfuric acid, hydrochloric acid, phosphoric acid, nitric acid, perchloric acid, formic acid and acetic acid. More preferably, it may be benzoic acid, formic acid and/or acetic acid.
In the present invention, the reaction solvent that is used in step 2) of preparing the crystalline form A of ilaprazole may be a lower (C1~C6) alkanol and/or a polar solvent. Specifically, the reaction solvent that is used in step 2) may be at least one selected from the group consisting of methanol, ethanol, propanol, xylene, toluene, tetrahydrofuran, 1,2-dichloromethane, acetone, ether, dichloromethane, acetonitrile, dimethylsulfoxide, dimethylformamide, and mixtures thereof. Preferably, it may be at least one selected from the group consisting of methanol, ethanol, propanol, tetrahydrofuran, acetone, and mixtures thereof. More preferably, it may be methanol, ethanol and/or propanol.
In the present invention, step 2) of preparing the crystalline form A of ilaprazole may be performed by stirringthe mixture at a temperature of 0 to 150 ℃, preferably 0 to 80 ℃, and more preferably room temperature to 50 ℃, but the stirring temperature is not specifically limited. Also, the stirring may preferably be carried out for 1-6 hours, but the stirring time is not specifically limited.
A preferred example of the process for preparing crystalline form A of ilaprazole according to the present invention is shown in the following reaction scheme 4.
[Reaction Scheme 4]
[Corrected under Rule 26 24.02.2011]
Figure WO-DOC-CHEMICAL-42
The process for preparing the crystalline form B of ilaprazole according to the present invention may include a step of preparing the crystalline form B of ilaprazole from ilaprazole in a reaction solvent.
In the present invention, the reaction solvent that is used in the step of preparing the crystalline form B of ilaprazole may be a lower (C1~C6) alkanol and/or a polar solvent. Specifically, the reaction solvent that is used in this step may be at least one selected from the group consisting of tetrahydrofuran, 1,2-dichloroethane, methanol, ethanol, propanol, acetone, dichloromethane, diethylether, ethylacetate, and mixtures thereof. More preferably, it may be at least one selected from the group consisting of methanol, ethanol, acetone, dichloromethane, diethylether, ethylacetate, and mixtures thereof.
In the step of preparing the crystalline form B of ilaprazole according to the present invention, a stabilizing agent may be added to the reaction solvent. A stabilizing agent that may be used in this step is not specifically limited, but it may be at least one selected from the group consistingof, for example, triethylamine, diethylamine, ethylenediamine, trimethylamine, diisopropylethylamine and pyridine.
In the present invention, the step of preparing the crystalline form B of ilaprazole may be performed by stirring the mixture at a temperature of 30 to 150 ℃, preferably 0 to 150 ℃, more preferably 0 to 80 ℃, and even more preferably room temperature to 50 ℃,but the stirring temperature is not specifically limited. Also, the stirring may preferably be carried out for 1-6 hours, but the stirring time is notspecifically limited.
A preferred example of the process for preparing the crystalline form B of ilaprazole according to the present invention is shown in the following reaction scheme.
[Reaction Scheme 5]
[Corrected under Rule 26 24.02.2011]
Figure WO-DOC-CHEMICAL-49
(Ilaprazole) (Crystalline form B)
In the processes for preparing the crystalline forms A and B according to the present invention, the starting material ilaprazole may be non-crystallized ilaprazole such as crude ilaprazole.
The process for converting crystalline forms of ilaprazole according to the present invention may include a step of converting the crystalline form A into crystalline form B of ilaprazole or converting the crystalline form B into crystalline form A of ilaprazole. In the step of converting the crystalline form A into crystalline form B of ilaprazole, a solvent that may be used when preparing the crystalline form B from ilaprazole may be used. Also, in the step of converting the crystalline form B into crystalline form A of ilaprazole, an inorganic salt, a reaction solvent and/or an acid, which may be used when preparing the crystalline form A from ilaprazole, may be used.
An example of the process for converting the crystalline forms of ilaprazole according to the present invention is shown in the following reaction scheme 6:
[Corrected under Rule 26 24.02.2011]
[Reaction Scheme 6]
Figure WO-DOC-CHEMICAL-54
The above and other objects, features and advantages of the present invention will be more apparent from the following detailed description taken in conjunction with the accompanying drawings, in which:
FIG. 1 is the XRPD diffraction pattern of the crystalline form A of ilaprazole according to the present invention;
FIG. 2 is the DSC thermogram of the crystalline form A of ilaprazole according to the present invention;
FIG. 3 is the IR spectrum of the crystalline form A of ilaprazole according to the present invention;
FIG. 4 is the 1H-NMR spectrum of the crystalline form A of ilaprazole according to the present invention;
FIG. 5 is the XRPD diffraction pattern of the crystalline form B of ilaprazole according to the present invention;
FIG. 6 is the DSC thermogram of the crystalline form B of ilaprazole according to the present invention;
FIG. 7 is the IR spectrum of the crystalline form B of ilaprazole according to the present invention; and
FIG. 8 is the 1H-NMR spectrum of the crystalline form B of ilaprazole according to the present invention.
Hereinafter, the present invention will be described in further detail with reference to examples. It is to be understood, however, that these examples are for illustrative purposes only and are not to be construed as limiting the scope of the present invention.
Example 1: Preparation of ilaprazole sodium salt
Sodium hydroxide (16.65 mole, 0.67 kg) was dissolved in 27.5 L of methanol, and ilaprazole (16.65 mole, 6.1 kg)was added thereto. Then, the mixture was stirred at room temperature for 24 hours. The produced solid was filtered, washed with 12 L of methanol, and then dried at 40 ℃ for 12 hours, thereby obtaining 5.9 kg (91% yield) of the pure title compound as white crystalline powder. The results of analysis of the obtained powder are as follows.
Melting point: 197 ℃
odium content: 5.5% (as anhydride; theoretical value: 5.92%)
1H-NMR (δ, DMSO-d6): 8.30 (1H,d), 7.52 (1H,d), 7.49 (1H,d), 7.20 (2H,t), 7.05 (1H,dd), 6.94 (1H,d), 6.19 (2H,t), 4.75 (1H,d), 4.43 (1H,d), 3.84 (3H,s), 2.16 (3H,s)
IR (KBr, cm-1): 3443.0, 1613.4, 1585.2, 1497.4, 1480.5, 1437.2, 1385.1, 1296.2, 1277.8, 1254.5, 1216.6, 1157.5, 1098.7, 1017.1, 981.6, 895.0, 815.4, 725.1
Example 2: Preparation of crystalline form A of ilaprazole
Ilaprazole sodium salt (12.87 mole, 5.0 kg) was added to 100 L of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 20 L of a 50% (v/v) ethanol aqueous solution, and then dried at 40 ℃for 12 hours, thereby obtaining 4.06 kg (86% yield) of the pure title compound as white crystalline powder. The results of analysis of the obtained powder are as follows.
Melting point: 154 ℃
1H-NMR (δ, DMSO-d6): 13.71 (1H,br), 8.22 (1H,d), 7.75 ((1H,br), 7.70 (1H,m), 7.52 (1H,m), 7.37 (2H,t), 6.94 (1H,d), 6.27 (2H,t), 4.78 (2H,q), 3.83 (3H,s), 2.13 (3H,s)
IR (KBr, cm-1): 3426.9, 3101.7, 1627.3, 1582.7, 1514.1, 1481.1, 1434.8, 1358.2, 1338.4, 1297.8, 1256.3, 1147.9, 1097.1, 1082.2, 1066.7, 1052.1, 1017.8, 964.1, 891.6, 867.3, 821.8, 732.3
DSC (onset): 169 ℃ (heating rate: 10 ℃/min)
XRPD data:
Figure PCTKR2010008767-appb-I000011
Example 3: Preparation of ilaprazole sodium salt
Sodium hydroxide (55.0 mmole, 2.2 g) was dissolved in 90 ml of ethanol, and ilaprazole (54.6 mmole, 20.0 g)was added thereto. Then, the mixture was stirred at room temperature for 24 hours. The produced solid was filtered, washed with 40 ml of ethanol, and then dried at 40 ℃ for 12 hours, thereby obtaining 18.7 g (88% yield)of the pure title compound as white crystalline powder.
Melting point: 196 ℃
Example 4: Preparation of ilaprazole sodium salt
Sodium hydroxide (55.0 mmole, 2.2 g) was dissolved in 90 ml of propanol, and ilaprazole (54.6 mmole, 20.0 g)was added thereto. Then, the mixture was stirred at room temperature for 24 hours. The produced solid was filtered, washed with 40 ml of propanol, and then dried at 40 ℃ for 12 hours, thereby obtaining 17.8 g (84% yield) of the pure title compound as white crystalline powder.
Melting point: 197 ℃
Example 5: Preparation of ilaprazole sodium salt
Sodium hydroxide (55.0 mmole, 2.2 g) was dissolved in 90 ml of methanol, and ilaprazole (54.6 mmole, 20.0 g)was added thereto. Then, the mixture was stirred at 50 ℃ for 24 hours. The produced solid was filtered, washed with 40 ml of methanol, and then dried at 40 ℃for 12 hours, thereby obtaining 17.2 g (81% yield) of the pure title compound as white crystalline powder.
Melting point: 196 ℃
Example 6: Preparation of crystalline form A of ilaprazole
Ilaprazole sodium salt (25.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of benzoic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 ℃for 12 hours, thereby obtaining 7.7 g (82% yield) of the pure title compound as white crystalline powder.
Melting point: 154 ℃
Example 7: Preparation of crystalline form A of ilaprazole
Ilaprazole sodium salt (25.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of formic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 ℃for 12 hours, thereby obtaining 8.1 g (86% yield) of the pure title compound as white crystalline powder.
Melting point: 153 ℃
Example 8: Preparation of ilaprazole potassium salt
Potassium hydroxide (54.6 mmole, 3.1 g) was dissolved in 110 ml of methanol, and ilaprazole (54.6 mmole, 20.0 g) was added thereto. Then, the mixture was stirred at room temperature for 24 hours. The produced solid was filtered, washed with 40 ml of methanol, and then dried at 40 ℃ for 12 hours, thereby obtaining 20.3 g (92% yield) of the pure title compound as white crystalline powder.
Melting point: 220 ℃
Potassium content: 9.5% (as anhydride theoretical value: 9.67%)
Example 9: Preparation of crystalline form A of ilaprazole
Ilaprazole potassium salt (24.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 ℃ for 12 hours, thereby obtaining 7.4 g (82% yield) of the pure title compound as white crystalline powder.
Melting point: 154 ℃
Example 10: Preparation of ilaprazole calcium salt trihydrate
Calcium chloride (24.4 mmole, 2.7 g) was dissolved in 330 ml of water, and ilaprazole sodium salt (51.5 mmole, 20.0 g) was added thereto. Then, the mixture was stirred at room temperature for 1hour. The produced solid was filtered, washed with 400 ml of water, and then dried at 40 ℃ for 12 hours, thereby obtaining 18.4 g (91% yield) of the pure title compound as white crystalline powder.
Melting point: 210 ℃
Calcium content: 5.1% (as anhydride; theoretical value: 5.2%)
Water content: 6.18% (theoretical value: 6.55%)
Example 11: Preparation of crystalline form A of ilaprazole
Ilaprazole calcium salt trihydrate (12.1 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours.Then, the produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 ℃ for 12 hours, thereby obtaining 7.5 g (84% yield) of the pure title compound as white crystalline powder.
Melting point: 154 ℃
Example 12: Preparation of ilaprazole magnesium salt dehydrate
Ilaprazole potassium salt (24.7 mmole, 10.0 g) was dissolved in 20 ml of water, and magnesium chloride (49.4 mmole, 4.7 g)was added thereto. Then, the mixture was stirred at room temperature for 4 hours. The produced solid was filtered, washed with 25 ml of methanol, and then dried at 40 ℃ for 12 hours, thereby obtaining 8.7 g (89% yield) of the pure title compound as white crystalline powder.
Melting point: 173 ℃
Magnesium content: 3.0% (as anhydride; theoretical value: 3.2%)
Water content: 4.5% (theoretical content: 4.55%)
Example 13: Preparation of ilaprazole magnesium salt trihydrate
Ilaprazole potassium salt (24.7 mmole, 10.0 g) was dissolved in 20 ml of water, and magnesium chloride (49.4 mmole, 4.7 g)was added thereto. Then, the mixture was stirred at room temperature for 4 hours. The produced solid was filtered, added to 75 ml of water and stirred at room temperature for 6 hours. The resulting solid was filtered, washed with 25 ml of methanol, and then dried at 40 ℃ for 12 hours, thereby obtaining 7.5 g (75% yield) of the pure title compound as white crystalline powder.
Melting point: 171 ℃
Magnesium content: 3.1% (as anhydride; theoretical value: 3.2%)
Water content: 6.3% (theoretical content: 6.67%)
Example 14: Preparation of ilaprazole magnesium salt tetrahydrate
Ilaprazole sodium salt (25.7 mmole, 10.0 g) was dissolved in 130 ml of water, and a solution of magnesium chloride (12.9 mmole, 1.2 g)in 48 ml of water was added thereto. Then, the mixture was stirred at room temperature for 1 hour. The produced solid was filtered, washed with 30 ml of water, and then dried at 40 ℃for 12 hours, thereby obtaining 9.8 g (92% yield) of the pure title compound as white crystalline powder.
Melting point: >170 ℃
Magnesium content: 3.3% (as anhydride; theoretical value: 3.2%)
Water content: 8.0% (theoretical content: 8.7%)
Example 15: Preparation of crystalline form A of ilaprazole
Ilaprazole magnesium salt tetrahydrate (12.1 mmole, 10.0 g)was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acd. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 ℃ for 12 hours, thereby obtaining 7.4 g (83% yield) of the pure title compound as white crystalline powder.
Melting point: 153 ℃
Example 16: Preparation of ilaprazole strontium salt dihydrate
Strontium chloride (hexahydrate) (30.9 mmole, 8.2 g) was dissolved in 120 mlof methanol, and a solution of ilaprazole sodium salt (51.5 mmole, 20.0 g) in 120 ml of water was added thereto. Then, the produced solid was filtered, washed with 120 ml of a mixed solvent of water and methanol, and then dried at 40 ℃ for 12hours, thereby obtaining 17.2 g (78% yield) of the pure title compound as white crystalline powder.
Melting point: 214 ℃
Strontium content: 10.4% (as anhydride; theoretical content: 10.7%)
Water content: 4.7% (theoretical value: 4.2%)
Example 17: Preparation of crystalline form A of ilaprazole
Ilaprazole strontium salt dehydrate (11.7 mmole, 10.0 g) was added to 200 ml of ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 40 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 ℃for 12 hours, thereby obtaining 7.0 g (82% yield) of the pure title compound as white crystalline powder.
Melting point: 154 ℃
Example 18: Preparation of crystalline form A of ilaprazole
Sodium hydroxide (55.0 mmole, 2.2 g) was dissolved in 300 ml of ethanol, and ilaprazole (54.6 mmole, 20.0 g)was added thereto. Then, the mixture was stirred at room temperature for 24 hours. The resulting suspension was neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid, and then stirred at room temperature for 2 hours. The produced solid was filtered, washed with 80 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 ℃ for 12 hours, thereby obtaining 15.1 g (76% yield) of the pure title compound as white crystalline powder.
Melting point: 153 ℃
Example 19: Preparation of Crystalline form B of ilaprazole
Ilaprazole (16.38 mole, 6.0 kg) was dissolved in 30 L of a mixed solvent of methanol and dichloromethane and added slowly to 150 L of diethylether. Then, the mixture was stirred at room temperature for 45 minutes. The producedsolid was filtered, washed with 3 L of diethylether, and then dried at 30 ℃ for 12 hours, thereby obtaining 5.1 kg (85% yield) of the pure title compound as white crystalline powder. The results of analysis of the obtained powder are as follows.
Melting point: 150 ℃
1H-NMR (δ, DMSO-d6): 13.72 (1H,br), 8.23 (1H,d), 7.77 (1H,br), 7.71 (1H,m), 7.52 (1H,m), 7.36 (2H,t), 6.93 (1H,d), 6.28 (2H,t), 4.79 (2H,q), 3.83 (3H,s), 2.14 (3H,s)
IR (KBr, cm-1): 3194.7, 3102.5, 1629.9, 1581.4, 1517.7, 1502.1, 1478.3, 1433.6, 1411.6, 1390.6, 1294.4, 1271.3, 1257.2, 1090.8, 1045.1, 1016.2, 892.6, 811.8
DSC(onset): 157 ℃ (heating rate: 10 ℃/min)
XRPD date:
Figure PCTKR2010008767-appb-I000012
Example 20: Preparation of crystalline form B of ilaprazole
Ilaprazole (54.6 mmole, 20.0 g) was dissolved in 260 ml of dichloromethane, and the solutionwas concentrated under reduced pressure to a volume of 80 ml. The concentrated ethyl acetate solution was added slowly to 266 ml of ethyl acetate, and then stirred at a temperature between -10 ℃ and -15 ℃ for about 3-4 hours. The produced solid was filtered, washed with 100 ml of diethylether, and then dried at 30 ℃ for 12 hours, thereby obtaining 17.8 g (89% yield) of the pure title compound as white crystalline powder.
Melting point: 150 ℃
Example 21: Preparation of crystalline form B of ilaprazole
Ilaprazol (27.3 mmole, 10.0 g) was dissolved in 130 ml of a mixed solvent of dichloromethane and triethylamine (1%, v/v), and 150 ml of acetone was added thereto. Then, the solution was concentrated under reduced pressure to a volume of 130 ml.130 ml of diethylether was added slowly to the concentrated solution, and the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 100 ml of diethylether, and then dried at 30 ℃ for 12 hours, thereby obtaining 8.1 g (81% yield) of the pure title compound as white crystalline powder.
Melting point: 149 ℃
Example 22: Preparation of crystalline form B of ilaprazole
Ilaprazole (27.3 mmole, 10.0 g) was dissolved in 130 ml of a mixed solvent of dichloromethane and triethylamine (1%, v/v), and 130 ml of diethylether was slowly added thereto. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 100 ml of diethylether, and then dried at 30 ℃ for 12 hours, thereby obtaining 7.6 g (76%yield) of the pure title compound as white crystalline powder.
Melting point: 150 ℃
Example 23: Conversion of crystalline form B of ilaprazole into crystalline form A of illaprazole
Sodium hydroxide (55.0 mmole, 2.2 g) was dissolved in 90 ml of methanol, and the crystalline form B of ilaprazole (54.6 mmole, 20.0 g) was added thereto. Then, the mixture was stirred at room temperature for 24 hours. The produced solid was filtered, washed with 40 ml of methanol, and then dried at 40 ℃ for 12 hours, thereby obtaining 19.1 gof pure ilaprazole sodium salt as white crystalline powder. The obtained ilaprazole sodium salt (49.2 mmole, 19.1 g) was added to 380 mlof ethanol and neutralized by slow addition of a 10% (w/w) ethanol solution of acetic acid. Then, the mixture was stirred at room temperature for 2 hours. The produced solid was filtered, washed with 75 ml of a 50% (v/v) ethanol aqueous solution, and then dried at 40 ℃ for 12 hours, thereby obtaining 15.3 g (77% yield) of the pure title compound as white crystalline powder.
Melting point: 154 ℃
Example 24: Conversion of crystalline form A of ilaprazole into crystalline form B of ilaprazole
The crystalline form A of ilaprazole (54.6 mmole, 20.0 g) was dissolved in 100 ml of a mixed solvent of methanol and dichloromethane and added slowly to 500 ml of diethylether. Then, the mixture was stirred at room temperature for 45 minutes. The produced solid was filtered, washed with 200 ml of diethylether, and then dried at 30 ℃ for 12 hours, thereby obtaining 16.6 g (83% yield) of the pure title compound as white crystalline powder.
Melting point: 150 ℃
Reference Example 1: Preparation of crystalline form A of ilaprazole according to the prior art
3% ammonia water/acetonitrile (6 kg) was placed in a flask. After the internal temperature of the flask has been controlled to 5 ℃, ilaprazole (0.4 kg)was placed in the flask and stirred for 1 hour. The resulting slurry was filtered, and the solid was washed with 3% ammonia water/acetonitrile (2 x 0.4 kg). The filtered solid was placed in a flask, and 0.5% ammonia water/ethanol (0.2 kg) was added thereto. Then, the mixture was concentrated under reduced pressure at a temperature of 20 to 25 ℃ such that it was not distilled. 0.5% ammonia water/ethanol (1.0 kg) was placed in the flask, and dichloromethane (2.4 kg) was added thereto. Then, the solution was concentrated under reduced pressure at a temperature of 20 to 25 ℃ to a volume of about 1.0 L. 0.5% ammonia water/ethanol (1.2 kg) was placed in the flask, and the solution was concentrated again under reduced pressure at a temperature of 20 to 25 ℃ to a volume of about 1.2 L. 0.5% ammonia water/ethanol (0.2 kg) was added to the concentrated solution, and the solution was cooled to about 5 ℃ and then stirred for 45 minutes. The resulting slurry was filtered and washed with 0.5% ammonia water/ethanol (0.2 kg), ethanol (0.2 kg) and MTBE (2 x 0.2 kg).The filtered solid was dried for 2 hours and vacuum-dried at a temperature of 92 ℃ or below for 92 hours, thereby obtaining 0.338 kg (85% yield) of the crystalline form A of ilaprazole.
Reference Example 2: Preparation of crystalline form B of ilaprazole according to the prior art
The crystalline form A of ilaprazole was added to 10 ml of acetone/triethylamine and sonicated at room temperature for about 5 minutes to make a saturated solution of ilaprazole. The slurry was filtered through a nylon filter into a glass vial. The filtered slurry was allowed to stand in a refrigerator for 11 days and then filtered, thereby obtaining a white crystalline form B of ilaprazole.
Although exemplary embodiments of the present invention have been described for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scopeand spirit of the invention as disclosed in the accompanying claims.

Claims (21)

  1. A process for preparing a crystalline form A of ilaprazole, comprising the steps of:
    1) preparing an inorganic salt of ilaprazole or a hydrate thereof from ilaprezole in the presence of an inorganic base and a reaction solvent; and
    2) neutralizing the produced inorganic salt of ilapazole or the hydrate thereof with an acid in a reaction solvent to prepare the crystalline form A of ilaprazole.
  2. The process of claim 1, further comprising, after step 1), a step of adding a heterogeneous inorganic salt to prepare a heterogeneous inorganic salt of ilaprazole or a hydrate thereof.
  3. The process of claim 1 or 2, wherein the inorganic base or inorganic salt in step 1) includes lithium, titanium, barium, zinc, sodium, potassium, calcium, magnesium or strontium.
  4. The process of claim 1 or 2, wherein the reaction solvent in step 1) is at least one selected from the group consisting of a C1~C6 alkanol and a polar solvent.
  5. The process of claim 4, wherein the reaction solvent in step 1) is at least one selected from the group consisting of methanol, ethanol, propanol, xylene, toluene, tetrahydrofuran, 1,2-dichloroethane, acetone, ether, dichloromethane, acetonitrile, dimethylsulfoxide and dimethylformamide.
  6. The process of claim 1 or 2, wherein step 2) of preparing the inorganic salt or inorganic salt hydrate of ilaprazole is carried out by stirring the mixture of ilaprazole, the inorganic base and the reaction solvent at a temperature of 0 to 150 ℃ for 1-48 hours.
  7. The process of claim 1 or 2, wherein the acid in step 2) is at least one selected from the group consisting of chloroacetic acid, benzoic acid, butyric acid, sulfuric acid, hydrochloric acid, phosphoric acid, nitric acid, perchloric acid, formic acid, acetic acid, propionic acid, succinic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, hydroxybenzenesulfonic acid and tartaric acid.
  8. The process of claim 1 or 2, wherein the reaction solvent in step 2) is at least one selected from the group consisting of a C1~C6 alkanol and a polar solvent.
  9. The process of claim 8, wherein the reaction solvent in step 2) is at least one selected from the group consisting of methanol, ethanol, propanol, xylene, toluene, tetrahydrofuran, 1,2-dichloromethane, acetone, ether, dichloromethane, acetonitrile, dimethylsulfoxide and dimethylformamide.
  10. The process of claim 1 or 2, wherein the step of preparing the crystalline form A of ilaprazole is carried out by stirring the mixture of the inorganicsalt or inorganic salt hydrate of ilaprazole and the reaction solvent at a temperature of 0 to 150 ℃ for 1-6 hours.
  11. The process of claim 1 or 2, wherein the process is carried out according to the following reaction scheme 4:
    [Corrected under Rule 26 24.02.2011]
    [Reaction Scheme 4]
    Figure WO-DOC-CHEMICAL-cl11
    .
  12. A process for preparing a crystalline form B of ilaprazole, comprising a step of preparing the crystalline form B of ilaprazole from ilaprazole in a reaction solvent.
  13. The process of claim 12, wherein the reaction solvent is at least one selected from the group consisting of a C1~C6 alkanol and a polar solvent.
  14. The process of claim 13, wherein the reaction solvent is at least one selected from the group consisting of tetrahydrofuran, 1,2-dichloroethane, methanol, ethanol, propanol, acetone, dichloromethane, diethylether and ethylacetate.
  15. The process of claim 12, wherein a stabilizing agent is additionally added to the reaction solvent.
  16. The process of claim 15, wherein the stabilizing agent is at least one selected from the group consisting of triethylamine, diethylamine, ethylenediamine, trimethylamine, diisopropylethylamine and pyridine.
  17. The process of claim 12, wherein the preparation of the crystalline form B of ilaprazole is performed by stirring the mixture of the crystalline form B of ilaprazole and the reaction solvent at a temperature of 30 to 150 ℃ for 1-6 hours.
  18. The process of any one of claims 12 to 17, wherein the process is carried out according to the following reaction scheme 5:
    [Corrected under Rule 26 24.02.2011]
    [Reaction Scheme 5]
    Figure WO-DOC-CHEMICAL-cl18
    (Ilaprazole) (Crystalline form B).
  19. A process for converting crystalline forms A and B of ilaprazole, comprising a step of converting the crystalline form A into crystalline form B of ilaprazole or the crystalline form B into crystalline form A of ilaprazole in the presence of a reaction solvent and/or, if necessary, an inorganic salt or an acid.
  20. The process of claim 19, wherein the reaction solvent is at least one selected from the group consisting of a C1~C6 alkanol and a polar solvent.
  21. The process of claim 19 or 20, wherein the process is carried out according to the following reaction scheme 6:
    [Corrected under Rule 26 24.02.2011]
    [Reaction Scheme 6]
    Figure WO-DOC-CHEMICAL-cl21
    .
PCT/KR2010/008767 2009-12-08 2010-12-08 Processes for preparing crystalline forms a and b of ilaprazole and process for converting the crystalline forms WO2011071314A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR112012012212A BR112012012212A2 (en) 2009-12-08 2010-12-08 processes for preparing crystalline forms a and b of ilaprazole and process for converting crystalline forms
EA201200716A EA019058B1 (en) 2009-12-08 2010-12-08 Processes for preparing crystalline forms a and b of ilaprazole and process for converting the crystalline forms
IN3176DEN2012 IN2012DN03176A (en) 2009-12-08 2010-12-08
UAA201207006A UA102787C2 (en) 2009-12-08 2010-12-08 Process for preparing crystalline forms a and b of ilaprazole and a process of the conversion of crystalline forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0121209 2009-12-08
KR1020090121209A KR101144600B1 (en) 2009-12-08 2009-12-08 Process for Preparing and Conversion of Ilaprazole Crystalline Form A, B

Publications (2)

Publication Number Publication Date
WO2011071314A2 true WO2011071314A2 (en) 2011-06-16
WO2011071314A3 WO2011071314A3 (en) 2011-11-10

Family

ID=44146052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/008767 WO2011071314A2 (en) 2009-12-08 2010-12-08 Processes for preparing crystalline forms a and b of ilaprazole and process for converting the crystalline forms

Country Status (7)

Country Link
KR (1) KR101144600B1 (en)
BR (1) BR112012012212A2 (en)
CO (1) CO6541539A2 (en)
EA (1) EA019058B1 (en)
IN (1) IN2012DN03176A (en)
UA (1) UA102787C2 (en)
WO (1) WO2011071314A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746275A (en) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 Crystallization-type ilaprazole sodium and preparation method thereof
CN102746277A (en) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 Crystal-form ilaprazole sodium and preparation method thereof
CN102746276A (en) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 Ilaprazole sodium crystal form and preparation method thereof
CN103204842A (en) * 2012-01-13 2013-07-17 丽珠医药集团股份有限公司 Crystalline Ilaprazole sodium hydrate and preparation method thereof
CN103204843A (en) * 2012-01-13 2013-07-17 丽珠医药集团股份有限公司 Crystalline Ilaprazole sodium ethylate and preparation method thereof
WO2013114232A1 (en) 2012-02-02 2013-08-08 Lupin Limited Process for preparation of crystalline form l of ilaprazole
CN105461692A (en) * 2014-09-04 2016-04-06 江苏奥赛康药业股份有限公司 Ilaprazole sodium compound and pharmaceutical composition thereof
CN107857756A (en) * 2017-11-06 2018-03-30 丽珠医药集团股份有限公司 A kind of Magnesium 2-((4-methoxy-3-methylpyridin-2-yl)methylsulfinyl)-5-(1H-pyrrol-1-yl)benzo[d crystal formation and preparation method thereof
CN111187255A (en) * 2020-01-13 2020-05-22 丽珠医药集团股份有限公司 Preparation method of dextro-ilaprazole potassium salt and preparation method of dextro-ilaprazole

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102027388B1 (en) * 2017-11-15 2019-10-01 주식회사 다산제약 Process for preparing high purity ilaprazole crystalline form B
KR20220065235A (en) 2020-11-13 2022-05-20 주식회사 파마코스텍 Process for the crystalline form of Ilaprazole
KR102250509B1 (en) * 2020-12-09 2021-05-11 유니셀랩 주식회사 Novel co-crystal of ilaprazole/xylitol
KR20210019469A (en) 2021-02-02 2021-02-22 주식회사 파마코스텍 Crystalline form of Ilaprazole sodium and its new process

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200515A1 (en) * 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
KR20090086121A (en) * 2006-12-29 2009-08-10 일양약품주식회사 Crystalline forms of solvated ilaprazole

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200515A1 (en) * 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
KR20090086121A (en) * 2006-12-29 2009-08-10 일양약품주식회사 Crystalline forms of solvated ilaprazole
KR20090086615A (en) * 2006-12-29 2009-08-13 일양약품주식회사 Solid state forms of racemic ilaprazole

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103204843B (en) * 2012-01-13 2014-12-31 丽珠医药集团股份有限公司 Crystalline Ilaprazole sodium ethylate and preparation method thereof
CN103204842B (en) * 2012-01-13 2014-10-15 丽珠医药集团股份有限公司 Crystalline Ilaprazole sodium hydrate and preparation method thereof
CN103204842A (en) * 2012-01-13 2013-07-17 丽珠医药集团股份有限公司 Crystalline Ilaprazole sodium hydrate and preparation method thereof
CN103204843A (en) * 2012-01-13 2013-07-17 丽珠医药集团股份有限公司 Crystalline Ilaprazole sodium ethylate and preparation method thereof
WO2013114232A1 (en) 2012-02-02 2013-08-08 Lupin Limited Process for preparation of crystalline form l of ilaprazole
CN102746275B (en) * 2012-06-21 2014-07-16 丽珠医药集团股份有限公司 Crystallization-type ilaprazole sodium and preparation method thereof
CN102746275A (en) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 Crystallization-type ilaprazole sodium and preparation method thereof
CN102746276A (en) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 Ilaprazole sodium crystal form and preparation method thereof
CN102746277A (en) * 2012-06-21 2012-10-24 丽珠医药集团股份有限公司 Crystal-form ilaprazole sodium and preparation method thereof
CN105461692A (en) * 2014-09-04 2016-04-06 江苏奥赛康药业股份有限公司 Ilaprazole sodium compound and pharmaceutical composition thereof
CN113045544A (en) * 2014-09-04 2021-06-29 江苏奥赛康药业有限公司 Ilaprazole sodium compound and pharmaceutical composition thereof
CN107857756A (en) * 2017-11-06 2018-03-30 丽珠医药集团股份有限公司 A kind of Magnesium 2-((4-methoxy-3-methylpyridin-2-yl)methylsulfinyl)-5-(1H-pyrrol-1-yl)benzo[d crystal formation and preparation method thereof
CN115403560A (en) * 2017-11-06 2022-11-29 丽珠医药集团股份有限公司 Ilaprazole magnesium crystal form and preparation method thereof
CN111187255A (en) * 2020-01-13 2020-05-22 丽珠医药集团股份有限公司 Preparation method of dextro-ilaprazole potassium salt and preparation method of dextro-ilaprazole
CN111187255B (en) * 2020-01-13 2021-07-20 丽珠医药集团股份有限公司 Preparation method of dextro-ilaprazole potassium salt and preparation method of dextro-ilaprazole

Also Published As

Publication number Publication date
KR101144600B1 (en) 2012-05-16
IN2012DN03176A (en) 2015-09-25
UA102787C2 (en) 2013-08-12
BR112012012212A2 (en) 2015-09-08
EA019058B1 (en) 2013-12-30
WO2011071314A3 (en) 2011-11-10
KR20110064545A (en) 2011-06-15
CO6541539A2 (en) 2012-10-16
EA201200716A1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
WO2011071314A2 (en) Processes for preparing crystalline forms a and b of ilaprazole and process for converting the crystalline forms
WO2016085221A2 (en) Heteroaryl amine derivative useful as protein kinase inhibitor
WO2010030132A9 (en) Purification method for adefovir dipivoxil
WO2013022243A2 (en) Novel biphenyl derivative or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising same as an active ingredient
WO2014058268A1 (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
WO2018194416A1 (en) Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin-2-yl)-1h-pyrazol-5-ol hydrochloride
WO2011004980A2 (en) Method for preparing tricyclic derivatives
EP2611776A2 (en) Production method of intermediate compound for synthesizing medicament
WO2011132901A2 (en) Novel benzamide derivatives
WO2010110622A2 (en) Novel crystal forms of adefovir dipivoxil and processes for preparing the same
WO2014010990A1 (en) Novel pyridine derivatives and method for preparation of intermediate compound for producing sulfonylurea herbicides using the same
WO2016108623A1 (en) Novel method for preparing thienopyrimidine compound and intermediates used therein
WO2022220612A1 (en) Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist
WO2015178663A1 (en) An improved manufacturing method of zabofloxacin
WO2012148246A2 (en) A preparation method of sitagliptin
WO2021045585A1 (en) Method for producing pyrimidinyl bipyridine compound and intermediate therefor
WO2021029450A1 (en) Novel pyrimidine sulfonamide derivative, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient
WO2017090991A1 (en) Method for purifying benzopyran derivative, crystal form thereof, and method for preparing crystal form
WO2018038297A1 (en) Novel salt of (r)-(1-methylpyrrolidin-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and crystal form thereof
WO2024025393A1 (en) Novel salt of imidazo[1,2-a]pyridine compound, crystalline form thereof, and preparation method
WO2023113458A1 (en) Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof
WO2020009374A1 (en) Novel 4-substituted oxazoloquinolinone derivatives, pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of allergic diseases including asthma or atopic dermatitis comprising same
WO2012050380A2 (en) Novel pyridyl benzoxazine derivatives, pharmaceutical composition comprising the same, and use thereof
WO2014098410A1 (en) Method for preparing bosentan monohydrate, novel intermediate used therefor, and method for preparing same
WO2023101115A1 (en) Preparation method for high purity 1-(1-(2-benzyl phenoxy)propan-2-yl)-2-methylpiperidine single isomer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836209

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 3176/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 201200716

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1201002276

Country of ref document: TH

Ref document number: 12097489

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: A201207006

Country of ref document: UA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012012212

Country of ref document: BR

122 Ep: pct application non-entry in european phase

Ref document number: 10836209

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112012012212

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120522